Search Results

You are looking at 11 - 20 of 1,744 items for :

  • "chemotherapy" x
Clear All
Full access

David H. Moore

DH . Combined chemotherapy and radiation therapy for cervical cancer . J Natl Compr Canc Netw 2004 ; 2 : 631 – 635 . 12. National Cancer Institute . Concurrent chemoradiation for cervical cancer . Clinical Announcement , Washington

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare

Full access

David H. Moore

Eifel PJ Lu J . Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: A randomized Radiation Therapy Oncology Group clinical trial . N Engl J Med 1999 ; 340 : 1137 – 1143 . 24

Full access

Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian and Abhay R. Shelke

-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices . J Clin Oncol 2003 ; 21 : 4524 – 4531 . 2 Gralla RJ Itri LM Pisko SE . Antiemetic efficacy of high-dose Metoclopramide: Randomized trials with placebo

Full access

Mary Cianfrocca and William J. Gradishar

treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women . J Clin Oncol 1998 ; 16 : 3439 – 3460 . 2. Carrick S Parker S Wilcken N . Single agent versus combination chemotherapy for

Full access

Joseph Rosales and Lucille A. Leong

Hochster HS Welles L Hart L . Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial (Abstr #241) . Presentation. GI ASCO 2005

Full access

Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber and Anusha Kalbasi

evidence regarding the role, number of agents, and timing of chemotherapy for the management of high-risk primary STS in adults. 12 – 26 Most recently, a randomized controlled trial (EORTC-STBSG 62931) comparing treatment with doxorubicin and ifosfamide

Full access

Saul N. Weingart, Elizabeth Brown, Peter B. Bach, Kirby Eng, Shirley A. Johnson, Timothy M. Kuzel, Terry S. Langbaum, R. Donald Leedy, Raymond J. Muller, Lee N. Newcomer, Susan O’Brien, Denise Reinke, Mark Rubino, Leonard Saltz and Ronald S. Walters

, ushering in a new era of oral chemotherapy. Capecitabine approval was followed by FDA approval of a number of oral small molecule inhibitors of a variety of defined targets, including imatinib in 2001, gefitinib in 2003, and erlotinib in 2004. Five more new

Full access

Keith D. Eaton and Renato G. Martins

/print certificate. Learning Objectives Upon completion of this activity, participants will be able to: Identify medications that have demonstrated efficacy as maintenance chemotherapy for NSCLC Describe clinical trials of maintenance therapy

Full access

Mary F. Mulcahy, Andrew O. Wahl and William Small Jr.

Stocken DD Friess H . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer . N Engl J Med 2004 ; 350 : 1200 – 1210 . 4 Neuhaus POH Post S Gellert K . A randomised, prospective, multicenter, phase